Linden Thomas Advisory Services LLC Sells 83 Shares of Insulet Co. (NASDAQ:PODD)

Linden Thomas Advisory Services LLC decreased its stake in Insulet Co. (NASDAQ:PODD) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,724 shares of the medical instruments supplier’s stock after selling 83 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Insulet were worth $2,278,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its stake in Insulet by 10.0% during the second quarter. Dimensional Fund Advisors LP now owns 146,746 shares of the medical instruments supplier’s stock worth $29,618,000 after buying an additional 13,351 shares during the period. Mercer Global Advisors Inc. ADV bought a new stake in shares of Insulet in the 2nd quarter worth about $158,000. Beck Bode LLC boosted its stake in shares of Insulet by 33.6% during the 2nd quarter. Beck Bode LLC now owns 93,187 shares of the medical instruments supplier’s stock worth $18,805,000 after purchasing an additional 23,426 shares during the period. Pacer Advisors Inc. grew its holdings in Insulet by 36.3% during the 2nd quarter. Pacer Advisors Inc. now owns 6,506 shares of the medical instruments supplier’s stock valued at $1,313,000 after purchasing an additional 1,734 shares during the last quarter. Finally, Sei Investments Co. raised its position in Insulet by 148.6% in the 2nd quarter. Sei Investments Co. now owns 29,289 shares of the medical instruments supplier’s stock worth $5,911,000 after purchasing an additional 17,507 shares during the period.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on PODD. Wells Fargo & Company boosted their target price on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Raymond James boosted their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Citigroup increased their target price on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. BTIG Research boosted their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Canaccord Genuity Group upped their price target on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $272.81.

Insulet Stock Performance

Shares of PODD stock opened at $280.35 on Friday. The company’s 50 day moving average is $267.25 and its 200 day moving average is $235.25. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The firm has a market cap of $19.66 billion, a price-to-earnings ratio of 48.01, a PEG ratio of 3.50 and a beta of 1.22. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $282.86.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.13. The business had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same period last year, the business posted $0.71 EPS. On average, sell-side analysts anticipate that Insulet Co. will post 3.22 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.